Survey of Ophthalmology
Volume 48, Issue 1 , Pages 12-38 , January 2003

Paraneoplastic Retinopathies and Optic Neuropathies

  • Jane W Chan, MD

      Affiliations

    • Corresponding Author InformationReprint address: Jane W. Chan, MD, Department of Internal Medicine, Division of Neurology, University of Nevada School of Medicine, 2040 W. Charleston Blvd., Suite 300, Las Vegas, NV, USA 89102

References 

  1. Aaronson RM, Graven KK, Tucci M, et al.  Non-neuronal enolase is an endothelial hypoxic stress protein. J Biol Chem. 1995;270:27752–27757
  2. Adamus G, Amundson D. Epitope recognition of recoverin in cancer associated retinopathy (evidence for calcium-dependent conformational epitopes). J Neurosci Res. 1996;45:863–872
  3. Adamus G, Amundson D, MacKay C, Gouras P. Long-term persistence of antirecoverin antibodies in endometrial cancer-associated retinopathy. Arch Ophthalmol. 1998;116:251–253
  4. Adamus G, Aptsiauri N, Guy J. Anti-enolase anti bodies in cancer- associated retinopathy. Invest Ophthalmol Vis Sci. 1993;34(Suppl):1485; [abstract]
  5. Adamus G, Guy J, Schmied JL, et al.  Role of anti-recoverin autoantibodies in cancer-associated retinopathy. Invest Ophthalmol Vis Sci. 1993;34:2626–2633
  6. Adamus G, Machnicki M, Elerding H, et al.  Antibodies to recoverin induce apoptosis of photoreceptor and bipolar cells in vivo. J Autoimmun. 1998;11:523–533
  7. Adamus G, Machnicki M, Seigel GM. Apoptotic retinal cell death induced by antirecoverin autoantibodies of cancer-associated retinopathy. Invest Ophthalmol Vis Sci. 1997;38:283–291
  8. Akhmedov NB, Piriev NI, Chang B, et al.  A deletion in a photoreceptor-specific nuclear receptor mRNA causes retinal degeneration in the rd7 mouse. Proc Natl Acad Sci USA. 2000;97:5551–5556
  9. Akoun GM, Scarna HM, Milleron BJ, et al.  Serum neuron-specific enolase. A marker for disease extent and response to therapy for small-cell lung cancer. Chest. 1985;87:39–43
  10. Alexander KR, Fishman GA, Peachey NS, et al.  On response defect in paraneoplastic night blindness with cutaneous malignant melanoma. Invest Ophthalmol Vis Sci. 1992;33:477–483
  11. Alexianu ME, Mohamed AH, Smith RG, et al.  Apoptotic cell death of a hybrid motoneuron cell line induced by immunoglobulins from patients with amyotrophic lateral sclerosis. J Neurochem. 1994;63:2365–2368
  12. Andreasson S, Ponjavic V, Ehinger B. Full-field electroretinogram in a patient with cutaneous melanoma-associated retinopathy. Acta Ophthalmol (Copenh). 1993;71:487–490
  13. Antoine JC, Honnorat J, Camdessanche JP, et al.  Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol. 2001;49:214–221
  14. Berson EL, Lessell S. Paraneoplastic night blindness with malignant melanoma. Am J Ophthalmol. 1988;106:307–311
  15. Blumenthal D, Schochet S, Gutmann L, et al.  Small-cell carcinoma of the lung presenting with paraneoplastic peripheral nerve microvasculitis and optic neuropathy. Muscle Nerve. 1998;21:1358–1359
  16. Boeck K, Hofmann S, Klopfer M, et al.  Melanoma-associated paraneoplastic retinopathy (case report and review of the literature). Br J Dermatol. 1997;137:457–460
  17. Boghen D, Sebag M, Michaud J. Paraneoplastic optic neuritis and encephalomyelitis. Report of a case. Arch Neurol. 1988;45:353–356
  18. Borkowski LM, Grover S, Fishman GA, Jampol LM. Retinal findings in melanoma-associated retinopathy. Am J Ophthalmol. 2001;132:273–275
  19. Boucher MC, Allaire GS. Cancer-associated retinopathy (a clinicopathological case report). Can J Ophthalmol. 1997;32:46–49
  20. Bret-Dibat C, Rougier MB, Le Rebeller MJ, Delaunay M. Melanoma-associated retinopathy. Apropos of a case and review of the literature. Bull Cancer. 1996;83:1019–1022
  21. Brink H, Deutman A, Beex L. Unusual retinal pigment epitheliopathy and choroidopathy in carcinomatosis (a rare case of cancer-associated retinopathy). Graefes Arch Clin Exp Ophthalmol. 1997;236:75
  22. Buchanan TA, Gardiner TA, Archer DB. An ultrastructural study of retinal photoreceptor degeneration associated with bronchial carcinoma. Am J Ophthalmol. 1984;97:277–287
  23. Campo E, Brunier MN, Merino MJ. Small cell carcinoma of the endometrium with associated ocular paraneoplastic syndrome. Cancer. 1992;69:2283–2288
  24. Carney DN, Marangos PJ, Ihde DC, et al.  Serum neuron-specific enolase (a marker for disease extent and response to therapy of small-cell lung cancer). Lancet. 1982;1:583–585
  25. Chant SM, Heckenlively J, Meyers-Elliott RH. Autoimmunity in hereditary retinal degeneration. I. Basic studies. Br J Ophthalmol. 1985;69:19–24
  26. Chen F, Figueroa DJ, Marmorstein AD, et al.  Retina-specific nuclear receptor (a potential regulator of cellular retinaldehyde-binding protein expressed in retinal pigment epithelium and Muller glial cells). Proc Natl Acad Sci USA. 1999;96:15149–15154
  27. Chen W, Cao W, Achyuthan AM, McGinnis JF. In vitro inhibition of antirecoverin immunoglobulin-mediated death of mammalian photoreceptor cells. J Neurosci Res. 2001;63:116–123
  28. Cogan DG, Kuwabara T, Currie J, Kattah J: [Paraneoplastic retinopathy simulating cone dystrophy with achromatopsia]. Klin Monatsbl Augenheilkd 197:156–8, 1990
  29. Coppeto JR, Monteiro ML, Cannarozzi DB. Optic neuropathy associated with chronic lymphomatous meningitis. J Clin Neuroophthalmol. 1988;8:39–45
  30. Crofts JW, Bachynski BN, Odel JG. Visual paraneoplastic syndrome associated with undifferentiated endometrial carcinoma. Can J Ophthalmol. 1988;23:128–132
  31. de la Sayette V, Bertran F, Honnorat J, et al.  Paraneoplastic cerebellar syndrome and optic neuritis with anti-CV2 antibodies (clinical response to excision of the primary tumor). Arch Neurol. 1998;55:405–408
  32. DuBois L, Sadun AA, Lawton TB. Inner retinal layer loss in complicated migraine. Case report. Arch Ophthalmol. 1988;106:1035–1037
  33. Eichen JG, Dalmau J, Demopoulos A, et al.  The photoreceptor cell-specific nuclear receptor is an autoantigen of paraneoplastic retinopathy. J Neuroophthalmol. 2001;21:168–172
  34. Eltabbakh GH, Hoogerland DL, Kay MC. Paraneoplastic retinopathy associated with uterine sarcoma. Gynecol Oncol. 1995;58:120–123
  35. Evans RM. The steroid and thyroid hormone receptor superfamily. Science. 1988;240:889–895
  36. Feigl B, Faschinger C, Soyer P. Melanoma-associated retinopathy versus abnormal retinal function due to interferon-alpha/Isotretinoin therapy in cutaneous malignant melanoma. Ophthalmologica. 2000;214:271–276
  37. Fernandez A, Kiefer J, Fosdick L, McConkey DJ. Oxygen radical production and thiol depletion are required for Ca(2+)-mediated endogenous endonuclease activation in apoptotic thymocytes. J Immunol. 1995;155:5133–5139
  38. Flynn MF, Fisherman GA, Adamus G. Antiretinal Müller cell antibodies in patients with melanoma associated and autoimmune retinopathy. Invest Ophthalmol Vis Sci. 2000;41(Suppl):567; [abstract]
  39. Garrigues HJ, Lark MW, Lara S, et al.  The melanoma proteoglycan (restricted expression on microspikes, a specific microdomain of the cell surface). J Cell Biol. 1986;103:1699–1710
  40. Gass JDM: Acute Vogt-Koyanagi-Harada-like syndrome occurring in a patient with metastatic cutaneous melanoma, in Saari KM (ed): Uveitis Update: Proceedings of the First International Symposium on Uveitis, 1984 May 16–19; Hanasaari, Espoo, Finland. Amsterdam, Elsevier Science, 1984, pp 407–8
  41. Gehrs K, Tiedeman J. Hemeralopia in an older adult. Surv Ophthalmol. 1992;37:185–189
  42. Gittinger JW, Smith TW. Cutaneous melanoma-associated paraneoplastic retinopathy (histopathologic observations). Am J Ophthalmol. 1999;127:612–614
  43. Grunwald GB, Klein R, Simmonds MA, Kornguth SE. Autoimmune basis for visual paraneoplastic syndrome in patients with small-cell lung carcinoma. Lancet. 1985;1:658–661
  44. Grunwald GB, Kornguth SE, Towfighi J, et al.  Autoimmune basis for visual paraneoplastic syndrome in patients with small cell lung carcinoma. Retinal immune deposits and ablation of retinal ganglion cells. Cancer. 1987;60:780–786
  45. Guy J, Aptsiauri N. Treatment of paraneoplastic visual loss with intravenous immunoglobulin (report of 3 cases). Arch Ophthalmol. 1999;117:471–477
  46. Haider NB, Jacobson SG, Cideciyan AV, et al.  Mutation of a nuclear receptor gene, NR2E3, causes enhanced S cone syndrome, a disorder of retinal cell fate. Nat Genet. 2000;24:127–131
  47. Harmon JP, Purvin VA, Guy J, et al.  Cancer-associated retinopathy in a patient with advanced epithelial ovarian carcinoma. Gynecol Oncol. 1999;73:430–432
  48. Haus AH, Palmowski AM, Gantenbein C. Ocular findings in 28 patients with cutaneous malignant melanoma (CMM). Invest Ophthalmol Vis Sci. 2000;41(Suppl):568; [abstract]
  49. Heckenlively JR, Fawzi AA, Oversier J, et al.  Autoimmune retinopathy (patients with antirecoverin immunoreactivity and panretinal degeneration). Arch Ophthalmol. 2000;118:1525–1533
  50. Heckenlively JR, Solish AM, Chant SM, Meyers-Elliott RH. Autoimmunity in hereditary retinal degenerations. II. Clinical studies (antiretinal antibodies and fluorescein angiogram findings). Br J Ophthalmol. 1985;69:758–764
  51. Hoh ST, Teh M, Chew SJ. Paraneoplastic optic neuropathy in nasopharyngeal carcinoma—report of a case. Singapore Med J. 1991;32:170–173
  52. Holder GE. Electrophysiological features of melanoma associated retinopathy (MAR). Invest Opthhalmol Vis Sci. 2000;41(Suppl):568; [abstract]
  53. Hollemann T, Bellefroid E, Pieler T. The Xenopus homologue of the Drosophila gene tailless has a function in early eye development. Development. 1998;125:2425–2432
  54. Honnorat J, Antoine JC, Derrington E. Antibodies to a subpopulation of glial cells and 166 kDa developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 1996;6:270–278
  55. Ing EB, Augsburger JJ, Eagle RC. Lung cancer with visual loss. Surv Ophthalmol. 1996;40:505–510
  56. Ishiguro Y, Kato K, Shimizu A, et al.  High levels of immunoreactive nervous system-specific enolase in sera of patients with neuroblastoma. Clin Chim Acta. 1982;121:173–180
  57. Jacobson DM: Paraneoplastic diseases of neuro-ophthalmologic interest, in Miller NR, Newman N (eds): Walsh & Hoyts Clinical Neuro-Ophthalmology. Baltimore: Williams and Wilkins, 1998, ed 5, pp 2497–51
  58. Jacobson DM, Adamus G. Retinal anti-bipolar cell antibodies in a patient with paraneoplastic retinopathy and colon carcinoma. Am J Ophthalmol. 2001;131:806–808
  59. Jacobson DM, Thirkill CE. Paraneoplastic cone dysfunction (an unusual visual remote effect of cancer). Arch Ophthalmol. 1995;113:1580–1582
  60. Jacobson DM, Thirkill CE, Tipping SJ. A clinical triad to diagnose paraneoplastic retinopathy. Ann Neurol. 1990;28:162–167
  61. Jacobson SG, Marmor MF, Kemp CM, Knighton RW. SWS (blue) cone hypersensitivity in a newly identified retinal degeneration. Invest Ophthalmol Vis Sci. 1990;31:827–838
  62. Kashiwabara K, Nakamura H, Kishi K, et al.  Cancer-associated retinopathy during treatment for small-cell lung carcinoma. Intern Med. 1999;38:597–601
  63. Kawamura S, Cox JA, Nef P. Inhibition of rhodopsin phosphorylation by non-myristoylated recombinant recoverin. Biochem Biophys Res Commun. 1994;203:121–127
  64. Kellner U, Bornfeld N, Foerster MH. Severe course of cutaneous melanoma associated paraneoplastic retinopathy. Br J Ophthalmol. 1995;79:746–752
  65. Kellner U, Bornfeld N, Foerster MH. Severe course of cutaneous melanoma associated retinopathy. Invest Ophthalmol Vis Sci. 1994;35:2117
  66. Keltner JL, Roth AM, Chang RS. Photoreceptor degeneration. Possible autoimmune disorder. Arch Ophthalmol. 1983;101:564–569
  67. Keltner JL, Thirkill CE. The 22-kDa antigen in optic nerve and retinal diseases. J Neuroophthalmol. 1999;19:71–83
  68. Keltner JL, Thirkill CE. Cancer-associated retinopathy vs recoverin-associated retinopathy. Am J Ophthalmol. 1998;126:296–302
  69. Keltner JL, Thirkill CE, Tyler NK, Roth AM. Management and monitoring of cancer-associated retinopathy. Arch Ophthalmol. 1992;110:48–53
  70. Keltner JL, Thirkill CE, Yip PT. Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome (eleven new cases and a review of 51 previously published cases). J Neuroophthalmol. 2001;21:173–187
  71. Kennedy MJ, Eustace P, O'Briain DS, Daly PA. Paraneoplastic papilloedema in neuroblastoma. Postgrad Med J. 1987;63:873–876
  72. Kikuchi T, Arai J, Shibuki H, et al.  Tubby-like protein 1 as an autoantigen in cancer-associated retinopathy. J Neuroimmunol. 2000;103:26–33
  73. Kim RY, Retsas S, Fitzke FW, et al.  Cutaneous melanoma-associated retinopathy. Ophthalmology. 1994;101:1837–1843
  74. Kiratli H, Thirkill CE, Bilgic S, et al.  Paraneoplastic retinopathy associated with metastatic cutaneous melanoma of unknown primary site. Eye. 1997;11:889–892
  75. Klingele TG, Burde RM, Rappazzo JA, et al.  Paraneoplastic retinopathy. J Clin Neuroophthalmol. 1984;4:239–245
  76. Kobayashi M, Takezawa S, Hara K, et al.  Identification of a photoreceptor cell-specific nuclear receptor. Proc Natl Acad Sci USA. 1999;96:4814–4819
  77. Kornguth SE, Kalinke T, Grunwald GB, et al.  Anti-neurofilament antibodies in the sera of patients with small cell carcinoma of the lung and with visual paraneoplastic syndrome. Cancer Res. 1986;46:2588–2595
  78. Kornguth SE, Klein R, Appen R, Choate J. Occurrence of anti-retinal ganglion cell antibodies in patients with small cell carcinoma of the lung. Cancer. 1982;50:1289–1293
  79. Lambrecht ER, van der Loos TL, van der Eerden AH. Retrobulbar neuritis as the first sign of the glucagonoma syndrome. Int Ophthalmol. 1987;11:13–15
  80. Lei B, Bush RA, Milam AH, Sieving PA. Human melanoma-associated retinopathy (MAR) antibodies alter the retinal ON-response of the monkey ERG in vivo. Invest Ophthalmol Vis Sci. 2000;41:262–266
  81. Livingston PO, Wong GY, Adluri S, et al.  Improved survival in stage III melanoma patients with GM2 antibodies (a randomized trial of adjuvant vaccination with GM2 ganglioside). J Clin Oncol. 1994;12:1036–1044
  82. Luiz JE, Lee AG, Keltner JL, et al.  Paraneoplastic optic neuropathy and autoantibody production in small-cell carcinoma of the lung. J Neuroophthalmol. 1998;18:178–181
  83. MacKay CJ, Gouras P, Roy M. Paraneoplastic cone dystrophy. Invest Ophthalmol Vis Sci. 1994;35(Suppl):2119; [abstract]
  84. MacKay CJ, Gouras P, Yamamoto S. S-cone and rod ERG's reduced in paraneoplastic retinal degeneration. Invest Ophthalmol Vis Sci. 1992;33(Suppl):1074; [abstract]
  85. Maeda A, Ohguro H, Nabeta Y, et al.  Identification of human antitumor cytotoxic T lymphocytes epitopes of recoverin, a cancer-associated retinopathy antigen, possibly related with a better prognosis in a paraneoplastic syndrome. Eur J Immunol. 2001;31:563–572
  86. Maeda T, Maeda A, Maruyama I, et al.  Mechanisms of photoreceptor cell death in cancer-associated retinopathy. Invest Ophthalmol Vis Sci. 2001;42:705–712
  87. Malik S, Furlan AJ, Sweeney PJ, et al.  Optic neuropathy (a rare paraneoplastic syndrome). J Clin Neuroophthalmol. 1992;12:137–141
  88. Marmor MF, Jacobson SG, Foerster MH, et al.  Diagnostic clinical findings of a new syndrome with night blindness, maculopathy, and enhanced S cone sensitivity. Am J Ophthalmol. 1990;110:124–134
  89. Masaoka N, Emoto Y, Sasaoka A, et al.  Fluorescein angiographic findings in a case of cancer-associated retinopathy. Retina. 1999;19:462–464
  90. Matsui Y, Mehta MC, Katsumi O, et al.  Electrophysiological findings in paraneoplastic retinopathy. Graefes Arch Clin Exp Ophthalmol. 1992;230:324–328
  91. McConkey DJ, Chow SC, Orrenius S, Jondal M. NK cell-induced cytotoxicity is dependent on a Ca2+ increase in the target. FASEB J. 1990;4:2661–2664
  92. McGinnis JF, Austin B, Klisak I, et al.  Chromosomal assignment of the human gene for the cancer-associated retinopathy protein (recoverin) to chromosome 17p13.1. J Neurosci Res. 1995;40:165–168
  93. Milam AH, Saari JC, Jacobson SG, et al.  Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy. Invest Ophthalmol Vis Sci. 1993;34:91–100
  94. Milam AH, Clinical aspects . paraneoplastic retinopathy. In:  Djamgoz MBA,  Archer SN,  Vallerga S editor. Neurobiology and Clinical Aspects of the Outer Retina. London: Chapman and Hall; 1995;p. 461–471
  95. Mizener JB, Kimura AE, Adamus G, et al.  Autoimmune retinopathy in the absence of cancer. Am J Ophthalmol. 1997;123:607–618
  96. Murphy MA, Thirkill CE, Hart WM. Paraneoplastic retinopathy (a novel autoantibody reaction associated with small cell lung carcinoma). J Neuroophthalmol. 1996;17:77–83
  97. Nudelman E, Hakomori S, Kannagi R, et al.  Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2. J Biol Chem. 1982;257:12752–12756
  98. Ohguro H, Ogawa K, Nakagawa T. Recoverin and Hsc 70 are found as autoantigens in patients with cancer- associated retinopathy. Invest Ophthalmol Vis Sci. 1999;40:82–89
  99. Ohguro H, Rudnicka-Nawrot M, Buczylko J, et al.  Structural and enzymatic aspects of rhodopsin phosphorylation. J Biol Chem. 1996;271:5215–5224
  100. Ohkawa T, Kawashima H, Makino S, et al.  Cancer-associated retinopathy in a patient with endometrial cancer. Am J Ophthalmol. 1996;122:740–742
  101. Ohnishi Y, Ohara S, Sakamoto T, et al.  Cancer-associated retinopathy with retinal phlebitis. Br J Ophthalmol. 1993;77:795–798
  102. Okel BB, Thirkill CE, Anderson K. An unusual case of melanoma-associated retinopathy. Ocul Immunol Inflamm. 1995;3:121–127
  103. Oohira A, Tamaki Y, Nagahara K, Nakanishi N. A case of paraneoplastic retinopathy. Jpn J Ophthalmol. 1993;37:28–31
  104. Palmer K, Moore J, Everard M, et al.  Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma. Hum Gene Ther. 1999;10:1261–1268
  105. Peek R, Verbraak F, Coevoet HM, Kijlstra A. Muller cell-specific autoantibodies in a patient with progressive loss of vision. Invest Ophthalmol Vis Sci. 1998;39:1976–1979
  106. Pillay N, Gilbert JJ, Ebers GC, Brown JD. Internuclear ophthalmoplegia and optic neuritis (paraneoplastic effects of bronchial carcinoma). Neurology. 1984;34:788–791
  107. Polans AS, Buczylko J, Crabb J, Palczewski K. A photoreceptor calcium binding protein is recognized by autoantibodies obtained from patients with cancer-associated retinopathy. J Cell Biol. 1991;112:981–989
  108. Polans AS, Burton MD, Haley TL, et al.  Recoverin, but not visinin, is an autoantigen in the human retina identified with a cancer-associated retinopathy. Invest Ophthalmol Vis Sci. 1993;34:81–90
  109. Polans AS, Witkowska D, Haley TL, et al.  Recoverin, a photoreceptor-specific calcium-binding protein, is expressed by the tumor of a patient with cancer-associated retinopathy. Proc Natl Acad Sci USA. 1995;92:9176–9180
  110. Potter MJ, Thirkill CE, Dam OM, et al.  Clinical and immunocytochemical findings in a case of melanoma-associated retinopathy. Ophthalmology. 1999;106:2121–2125
  111. Remulla JF, Pineda R, Gaudio AR, Milam AH. Cutaneous melanoma-associated retinopathy with retinal periphlebitis. Arch Ophthalmol. 1995;113:854–855
  112. Richter RB, Moore RY. Non-invasive central nervous system disease associated with lymphoid tumors. Johns Hopkins Med J. 1968;122:271–283
  113. Ries LAG, Eisner MP, Kosary CL, et al (eds): SEER Cancer Statistics Review, 1973–1999, National Cancer Institute. Bethesda, MD, HYPERLINK http://seer.cancer.gov/csr/1973-1999/
  114. Ripps H, Carr RE, Siegel IM, Greenstein VC. Functional abnormalities in vincristine-induced night blindness. Invest Ophthalmol Vis Sci. 1984;25:787–794
  115. Rizzo JF, Gittinger JW. Selective immunohistochemical staining in the paraneoplastic retinopathy syndrome. Ophthalmology. 1992;99:1286–1295
  116. Rougier MB, Hostyn P, Bret-Dibat C, et al: [Paraneoplastic retinopathy associated with cutaneous melanoma. An update apropos of a case]. J Fr Ophtalmol 18:396–403, 1995
  117. Rudge P. Optic neuritis as a complication of carcinoma of the breast. Proc R Soc Med. 1973;66:1106–1107
  118. Rush JA. Paraneoplastic retinopathy in malignant melanoma. Am J Ophthalmol. 1993;115:390–391
  119. Salgia R, Hedges TR, Rizk M, et al.  Cancer-associated retinopathy in a patient with non-small-cell lung carcinoma. Lung Cancer. 1998;22:149–152
  120. Sawyer RA, Selhorst JB, Zimmerman LE, Hoyt WF. Blindness caused by photoreceptor degeneration as a remote effect of cancer. Am J Ophthalmol. 1976;81:606–613
  121. Singh AD, Milam AH, Shields CL, et al.  Melanoma-associated retinopathy. Am J Ophthalmol. 1995;119:369–370
  122. Sobottka B, Schlote T, Besch D, et al: [Carcinoma-associated retinopathy: a review with clinical examples]. Klin Monatsbl Augenheilkd 216:17–24, 2000
  123. Suzuki T, Obara Y, Sato Y, et al.  Cancer-associated retinopathy with presumed vasculitis. Am J Ophthalmol. 1996;122:125–127
  124. Thambisetty MR, Scherzer CR, Yu Z, et al.  Paraneoplastic optic neuropathy and cerebellar ataxia with small cell carcinoma of the lung. J Neuroophthalmol. 2001;21:164–167
  125. Thirkill CE. Retinal pigment epithelial hypersensitivity, an association with vision loss (RPE hypersensitivity complicating paraneoplastic retinopathies). Ocul Immunol Inflamm. 2000;8:25–37
  126. Thirkill CE, FitzGerald P, Sergott RC, et al.  Cancer-associated retinopathy (CAR syndrome) with antibodies reacting with retinal, optic-nerve, and cancer cells. N Engl J Med. 1989;321:1589–1594
  127. Thirkill CE, Keltner JL. Commonalities and diversity in the immune response of cancer-associated retinopathy (CAR) patients. Invest Ophthalmol Vis Sci. 1997;37(Suppl):S112; [abstract]
  128. Thirkill CE, Keltner JL, Tyler NK, Roth AM. Antibody reactions with retina and cancer-associated antigens in 10 patients with cancer-associated retinopathy. Arch Ophthalmol. 1993;111:931–937
  129. Thirkill CE, Roth AM, Keltner JL. Cancer-associated retinopathy. Arch Ophthalmol. 1987;105:372–375
  130. Thirkill CE, Tait RC, Tyler NK, et al.  The cancer-associated retinopathy antigen is a recoverin-like protein. Invest Ophthalmol Vis Sci. 1992;33:2768–2772
  131. van der Pol BA, Planten JT. A non-metastatic remote effect of lung carcinoma. Doc Ophthalmol. 1987;67:89–94
  132. Vaphiades MS, Brown H, Whitcup SM. Node way out. Surv Ophthalmol. 2000;45:77–83
  133. Waterston JA, Gilligan BS. Paraneoplastic optic neuritis and external ophthalmoplegia. Aust NZ J Med. 1986;16:703–704
  134. Weinstein JM, Kelman SE, Bresnick GH, Kornguth SE. Paraneoplastic retinopathy associated with antiretinal bipolar cell antibodies in cutaneous malignant melanoma. Ophthalmology. 1994;101:1236–1243
  135. Whitcup SM, Vistica BP, Milam AH, et al.  Recoverin-associated retinopathy (a clinically and immunologically distinctive disease). Am J Ophthalmol. 1998;126:230–237
  136. Wolf JE, Arden GB. Selective magnocellular damage in melanoma-associated retinopathy (comparison with congenital stationary nightblindness). Vision Res. 1996;36:2369–2379
  137. Wolf JE, Arden GB, Plant GT. Selective damage to either the M or P cell pathway in human retinal disease (implications for visual processing). Eur J Ophthalmol. 1996;6:208–214
  138. Wyllie AH, Arends MJ, Morris RG, et al.  The apoptosis endonuclease and its regulation. Semin Immunol. 1992;4:389–397
  139. Yoon YH, Cho EH, Sohn J, Thirkill CE. An unusual type of cancer-associated retinopathy in a patient with ovarian cancer. Korean J Ophthalmol. 1999;13:43–48
  140. Yu Z, Kryzer TJ, Griesmann GE, et al.  CRMP-5 neuronal autoantibody (marker of lung cancer and thymoma-related autoimmunity). Ann Neurol. 2001;49:146–154

PII: S0039-6257(02)00416-2

Survey of Ophthalmology
Volume 48, Issue 1 , Pages 12-38 , January 2003

Article Tools

* Image Usage & Resolution